法国生物技术EVerZom在2026年试验中筹集了1 000万欧元,用于推进克罗恩病瘘的刺激治疗。 French biotech EVerZom raises €10M to advance exosome therapy for Crohn’s disease fistulas in 2026 trial.

法国生物科技公司EVerZom获得了1000万欧元的资金, 以推进其基于外体的治疗方法EVerGelTM, 用于治疗克罗恩病的复杂周囊. French biotech EVerZom has secured €10 million in funding to advance its exosome-based therapy, EVerGel™, for treating complex perianal fistulas in Crohn’s disease. 这项投资由Capital Grand Est、EIC基金等牵头,将支助计划于2026年进行的人类首次临床试验。 The investment, led by Capital Grand Est, the EIC Fund, and others, will support a planned first-in-human clinical trial in 2026. EVerGelTM将外观与水文凝胶相结合,在动物模型中显示有87.5%的愈合率。 EVerGel™, which combines exosomes with a hydrogel, showed 87.5% healing in animal models. 该公司旨在扩展到肝病学和皮肤病学,开发新的候选人,规模生产,并建立伙伴关系,将异体疗法作为新的医疗类别。 The company aims to expand into hepatology and dermatology, develop new candidates, scale production, and form partnerships to establish exosome therapies as a new medical class.